Skip to main content

Muehl Daniel W's Form 4 filing

Clovis Oncology, Inc. (CLVS) · filed Aug 3, 2021

Accession no.
0000899243-21-031443
Filed
Aug 3, 2021
Trade date
Aug 1-3, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $21.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Muehl Daniel WCIK 0001283569Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 1, 2021Common StockMOption exerciseAcquired+5,624–F1–60,932Direct
Aug 3, 2021Common StockSSaleDisposed−2,473$4.82F3−$11,919.8658,459Direct
Aug 1, 2021Common StockMOption exerciseAcquired+4,625–F1–63,084Direct
Aug 3, 2021Common StockSSaleDisposed−2,034$4.82F3−$9,803.8861,050Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 1, 2021Common StockMOption exerciseDisposed−5,624$0.00$033,743Direct
Aug 1, 2021Common StockMOption exerciseDisposed−4,625$0.00$046,250Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit represents the right to receive one share of Common Stock.

Referenced by the price of 2 transactions in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $4.82 to $4.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 2 transactions in Table I.

Remarks

Executive Vice President and Chief Financial Officer

Read the full filing on SEC EDGAR (opens in a new tab)